Bilateral Salpingectomy with Oophorectomy

PROCEDURE2 trials

Sponsors

NRG Oncology, M.D. Anderson Cancer Center

Conditions

FIGO Grade 1 Endometrial Endometrioid AdenocarcinomaFIGO Grade 2 Endometrial Endometrioid AdenocarcinomaOvarian Carcinoma

Unknown Phase

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

RecruitingNCT04251052

NRG OncologyOvarian Carcinoma

Start: 2020-09-01End: 2047-06-30Target: 1956Updated: 2026-03-27

Prediction of Recurrence Among Low Risk Endometrial Cancer Patients

Active, not recruitingNCT04604613

M.D. Anderson Cancer CenterFIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma

Start: 2012-11-08End: 2026-12-31Updated: 2026-03-09

Related Papers

Optimization of Timing for Risk-Reducing Salpingectomy and Oophorectomy

Obstetrics and Gynecology2024-11-073 citations

OCRA encourages fallopian tube removal for women undergoing pelvic surgeries for benign conditions

Cancer2023-06-22

TUBectomy with delayed oophorectomy as an alternative to risk-reducing salpingo-oophorectomy in high-risk women to assess the safety of prevention: the TUBA-WISP II study protocol.

2023-06-0532 citations

NRG-CC008: A nonrandomized prospective clinical trial comparing the non-inferiority of salpingectomy to salpingo-oophorectomy to reduce the risk of ovarian cancer among BRCA1 carriers [SOROCk].

Journal of Clinical Oncology2022-06-0110 citations